Industry Revenue Breakdown:

• Pharmaceutical Research and Development: 70%
• Medication Distribution: 20%
• Licensing Fees and Partnerships: 10%

TOP 3 Markets:

• China: 50%
• USA: 30%
• Europe: 15%

Ascentage Pharma Group International generates the majority of its revenue from pharmaceutical research and development, attributed to its strong pipeline of medications in oncology and other therapeutic areas. Medication distribution also contributes significantly to revenue, while licensing fees and partnerships make up a smaller but important share.

The Chinese market is the company's largest single market, followed by the USA, which has gained importance in recent years through strategic partnerships and approvals. Europe represents the third largest market, with growth potential also existing through further market approvals.

Production Site: Suzhou, China

Ascentage Pharma Group International mainly produces its products in Suzhou, China. The location is strategically chosen to benefit from the well-developed infrastructure and technological resources of the region. Suzhou also provides access to a wide network of suppliers and skilled workers, supporting the company's production capacities.

Focus on R&D Investments: 35% of Revenue (2025)
Expansion of Clinical Trials: 10 New Studies in the Pipeline (2026)
Market Expansion: Planned Market Entries in Europe and North America (2026)

Ascentage Pharma Group International is pursuing a growth strategy that heavily emphasizes research and development (R&D). In 2025, the company invested 35% of its revenue in R&D to expand its pipeline of innovative drugs. These investments are intended to accelerate the development of new therapies and enhance competitiveness in the global market.

Additionally, Ascentage Pharma plans to expand its clinical trials, with 10 new studies in the pipeline for 2026. These studies focus on various oncological indications, increasing the potential for future market approvals and revenue growth.

Another strategic move is market expansion in Europe and North America. These regions offer significant growth opportunities as they represent large markets with high demand for innovative cancer treatments. By entering these markets, Ascentage Pharma aims to strengthen its global presence and significantly increase revenue.

Main raw materials: Chemical active ingredients, pharmaceutical intermediates
Countries of origin: China, India, USA

Ascentage Pharma Group International mainly imports chemical active ingredients and pharmaceutical intermediates needed for the production of their medications. These materials primarily come from China and India, known as leading producers of pharmaceutical raw materials. Additionally, the company sources some specialized materials from the USA to meet specific requirements in drug development.

This import strategy enables Ascentage Pharma to benefit from the cost-effective production capacities in Asia while ensuring quality by sourcing specialized materials from the USA.

Market share in oncology: 5% (estimated for 2026)
R&D investments: 30% of revenue (2025)
Patents: Over 100 active patents (2026)

Ascentage Pharma Group International has gained a significant competitive advantage through its strong investments in research and development. With 30% of revenue allocated to R&D, the company demonstrates a strong commitment to innovation, particularly in oncology.

The company holds more than 100 active patents that enhance its position in the field of targeted cancer therapies. These patents provide protection against imitative products and secure Ascentage Pharma a technological edge.

Despite an estimated market share of 5% in oncology, which is moderate compared to larger pharmaceutical companies, the focus on specialized therapies and continuous pipeline development enables the company to establish itself in niche markets.

Institutional Investor Share: approximately 40% (estimated for 2026 based on trends until 2023)

Insider Purchases/Sales: No specific data available for 2026

The institutional investor share in Ascentage Pharma Group International was recently around 40%, based on trends until 2023. However, this number may change over the years, depending on the market performance and strategic decisions of the company.

There is no specific data available for insider purchases and sales in 2026. Typically, such activities are disclosed in annual reports or through regulatory filings. It is advisable to review the latest reports and stock exchange announcements to obtain current information.

Market share of Ascentage Pharma Group International: Estimated 2-3% (2026)

Top competitors and their market shares:

1. Roche Holding AG: 15%
2. Novartis AG: 12%
3. Pfizer Inc.: 10%
4. Merck & Co., Inc.: 9%
5. AstraZeneca plc: 8%
6. Johnson & Johnson: 7%
7. Bristol-Myers Squibb Company: 6%
8. GlaxoSmithKline plc: 5%
9. Sanofi S.A.: 4%
10. Ascentage Pharma Group International: 2-3%

Moat of Ascentage Pharma:

Ascentage Pharma Group International specializes in the development of therapies for cancer and chronic diseases. Their moat mainly consists of their innovative pipeline and proprietary technologies, especially in the field of apoptosis modulation. This specialization can be seen as a certain advantage as they cater to niche markets that may not be as focused on by larger pharmaceutical companies to the same extent.

However, compared to major pharmaceutical companies like Roche or Novartis, which have extensive resources, established brands, and a wide range of products, the moat of Ascentage Pharma is less pronounced. These larger companies have significant advantages in terms of research capabilities, distribution channels, and financial strength.

In summary, Ascentage Pharma has a certain advantage in their niche, but compared to the top pharmaceutical companies, they have a weaker moat. The competition often has stronger financial resources and a broader market presence, giving them an edge.

Revenue Growth: 18% (2025) Research and Development Expenses: 35% of revenue (2025) Pipeline Progress: 3 drugs in Phase III (2026)

Ascentage Pharma Group International shows strong revenue growth of 18% in 2025, indicating successful commercialization of their products and effective market expansion. A significant portion of revenue, 35%, is invested in research and development, highlighting the company's commitment to innovation and future growth.

The company's pipeline is promising, with three of their drugs in Phase III of clinical trials. This suggests potential future revenue streams that could further strengthen the company.

Overall, Ascentage Pharma's financial and strategic position suggests that the stock could be an attractive investment opportunity, especially for investors interested in long-term growth.

Dividend: No payout (as of 2026)

Ascentage Pharma Group International has not distributed any dividends to its shareholders so far. The company is in a growth phase and reinvests its profits in research and development as well as in expanding its product pipeline.

Since Ascentage Pharma is strongly focused on innovation and the development of new drugs, it is unlikely that dividends will be paid in the near future. Investors should rather focus on capital growth than on regular dividend payouts.